Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Akero Therapeutics Inc (NASDAQ: AKRO) closed at $37.36 in the last session, up 9.75% from day before closing price of $34.04. In other words, the price has increased by $9.75 from its previous closing price. On the day, 2.25 million shares were traded. AKRO stock price reached its highest trading level at $38.015 during the session, while it also had its lowest trading level at $31.8.
Ratios:
We take a closer look at AKRO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.38 and its Current Ratio is at 19.38. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 07 ’25 when PATRICK D LAMY bought 8,000 shares for $36.73 per share.
Graham G. Walmsley bought 91,309 shares of AKRO for $4,085,804 on Mar 25 ’25. The Director now owns 1,091,309 shares after completing the transaction at $44.75 per share. On Mar 26 ’25, another insider, Graham G. Walmsley, who serves as the Director of the company, bought 58,691 shares for $43.01 each. As a result, the insider paid 2,524,417 and bolstered with 1,150,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 2974606848 and an Enterprise Value of 2217486336.
Stock Price History:
The Beta on a monthly basis for AKRO is 0.08, which has changed by 0.71062267 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $17.86. The 50-Day Moving Average of the stock is -19.63%, while the 200-Day Moving Average is calculated to be 14.39%.
Shares Statistics:
According to the various share statistics, AKRO traded on average about 1.44M shares per day over the past 3-months and 1524930 shares per day over the past 10 days. A total of 72.38M shares are outstanding, with a floating share count of 70.68M. Insiders hold about 11.23% of the company’s shares, while institutions hold 86.62% stake in the company. Shares short for AKRO as of 1741910400 were 5203442 with a Short Ratio of 3.62, compared to 1739491200 on 4785670. Therefore, it implies a Short% of Shares Outstanding of 5203442 and a Short% of Float of 6.7.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
